Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™

By X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando, J. Alimonti, H. Fausther-Bovendo, Haiyan Wei, J. Aviles, E. Hiatt and 16 more. Nature, 2014

976 citations recorded by the source corpus.

Without an approved vaccine or treatments, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa. Here we show that a combination of monoclonal antibodies (ZMapp), optimized from two previous antibody cocktails, is able to rescue 100% of rhesus macaques when treatment is initiated up to 5 days post-challenge. High fever, viraemia and abnormalities in blood count and blood chemistry were evident in many animals before ZMapp intervention. Advanced disease, as indicated by elevated liver enzymes, mucosal haemorrhages and generalized petechia could be reversed, leading to full recovery. ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola. ZMapp exceeds the efficacy of any other therapeutics described so far, and results warrant further development of this cocktail for clinical use.

Subfields: Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/1eeaeba0a53a4f8ebdd7340bed1a1c255097d1ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

Citations in the corpus

SARS-like WIV1-CoV poised for human emergence (2016, methodology): “Qiu X, et al. (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.”
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen (2017, methodology): “Thus, the use of a mixture of antibodies, including some directed against non-RBD epitopes, is a preferred strategy (29) and has been used successfully for the treatment of Ebola virus disease (30).”
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein (2019, positive): “Passive immunization with a combi nation of antibodies targeting di ﬀ erent domains and functions of the viral glycoprotein might be more pro tective against virus infection than single epitope mAb therapy, as was shown for other enveloped RNA viruses [31, 32, 41 43].”
Naïve Human Antibody Libraries for Infectious Diseases (2018, background): “Several antibody cocktails against EBOV were developed in recent years, which includes ZMAb [184] , MB-003 [185] , ZMapp [186] and the combination of mAB114 with mAb100 [187] that demonstrates successful therapeutic activity.”